In this case, high-quality evidence is limited, but this strategy is often used in routine clinical practice in the absence of alternative therapies, especially in patients with good performance status [15, 16]; (4) specific treatments for selected populations, such as dual inhibition of HER2 in HER2-positive CRC (i.e., tucatinib plus trastuzumab), immunotherapy in MSI-H, and intrahepatic therapies in limited disease or primarily located in the liver, although the main recommendation is to include patients in clinical trials [17]. This evidence concerns the gene ERBB2 and colorectal carcinoma.